
According to Czech media on October 23, a new European directive has been implemented, stating that as of October 23, tobacco products with distinct flavors or aromas must be removed from the Czech market.
In parallel, British American Tobacco (BAT) has recently launched another nicotine alternative called veo™. This product utilizes the same principles of usage as their previous offering, neopod, and is compatible with the glo device. It contains ingredients such as Louisianan Boswellia but is tobacco-free, offering five different flavors.
Regional leaders from BAT Czech, Slovakia, and Hungary state that nicotine alternatives will effectively reduce the number of smokers, and the launch of Veo™ is a further step in that direction.
According to reports, this new type of nicotine product has been introduced to the Czech market for the first time. It offers users a variety of flavor options and serves as a substitute for nicotine.
A series of regulations being implemented by the European Commission is currently facing resistance from tobacco companies in countries like Ireland, as they believe that the Commission is abusing its power.
In response, the European Court of Justice has agreed to review the reasonability of the ban on the sale of flavored heated tobacco products, while experts from various sectors continue to debate the increasingly stringent legislation on nicotine substitutes.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com